Zotepine

Zotepine
Clinical data
Trade names	Zoleptil
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N05AX11 (WHO) ;
Legal status
Legal status	BR: Class C1 (Other controlled substances); In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	7–13% (oral)
Metabolism	N-desmethylation to norzotepine (30-40%)
Elimination half-life	13.7–15.9 hours, 12 hours (Norzotepine)
Excretion	17% (Urine)
Identifiers
	IUPAC name 2-(3-chlorobenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethylethanamine;
CAS Number	26615-21-4 ;
PubChem CID	5736;
IUPHAR/BPS	103;
DrugBank	DB09225 ;
ChemSpider	5534 ;
UNII	U29O83JAZW;
KEGG	D01321 ;
ChEBI	CHEBI:32316 ;
ChEMBL	ChEMBL285802 ;
PDB ligand	ZOT (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID9023756 ;
ECHA InfoCard	100.189.143
Chemical and physical data
Formula	C18H18ClNOS
Molar mass	331.86 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc2cc1C(/OCCN(C)C)=C\c3c(Sc1cc2)cccc3;
	InChI InChI=1S/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3 ; Key:HDOZVRUNCMBHFH-UHFFFAOYSA-N ;
	(what is this?) (verify)

Zotepine is an atypical antipsychotic drug indicated for acute and chronic schizophrenia. It has been used in Germany since 1990 (although it has been discontinued in Germany) and Japan since 1982.

Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.